Blog
Published October 31, 2022
Executive Summary:
Germany’s ‘Financial Stabilization of Statutory Health Insurance System’ Act (GKV-Finanzstabilisierungsgesetz) was first proposed in March 2022 by Health Minister Professor Karl Lauterbach to help tackle the country’s economic deficit
Updated (January 13, 2023): The act was adopted by the Bundestag (German Federal Parliament) in October 2022. Most reforms have entered into force in November 2022, with the exception of the reduced sales threshold for orphan drugs (December 2022), the increased manufacturer rebate (January 2023) and the additional rebate…
Read Now
Scientific Publications
Autoimmune screening panel (ASP) is routinely ordered as a part of diagnostic work-up in people with suspected multiple sclerosis (MS). However, data on prevalence and significance of ASP seropositivity in MS is scarce.
Authors
D. Bandari, M. Adamson, M. Bowman, A. Gutierrez, A. Athavale, B. Oak, N. Hadker, F. Branco, C. Geremakis, J. B. Lewin, S. L. Shankar
Journal
ECTRIMS 2022
View publication…
Read Now
White Papers
Digital therapeutics (DTx) are impacting how patients are treated, interact with their providers and think about their own health. DTx have garnered interest from the investment community as well as pharma companies seeking an integrated digital offering. However, payers have not yet established a clear framework for integrating these technologies in their plans.
Coverage of DTx to date has been limited and the outlook for it is unclear. We spoke to four medical and pharmacy directors from large payer organizations…
Read Now
Blog
Published October 14, 2022
Executive Summary
The “ANS rol” defines the minimum mandatory coverage of services (diagnostics, procedures, and treatments) in the private sector. While private providers could opt to provide coverage beyond this list, in practice, the “ANS rol” has traditionally been seen as the maximum coverage that would be provided with anything beyond the “ANS Rol” being typically rejected
Law 14.454/2022 published in September 2022 establishes that the “ANS Rol” will dictate the minimum coverage that private payers need to provide, but…
Read Now
Webinars
Available On Demand
Secure success in bringing your novel therapies to market with Trinity’s innovative, holistic approach to valuing early-stage assets.
Biopharma companies have been experiencing record levels of growth in recent years through M&A, co-developments, joint ventures, licensing agreements and other partnership deals. It is unlikely that this accelerated growth would have been sustained using traditional methodologies that are less able to generate realistic valuations for complex innovative therapies. Using traditional valuation methods, we likely would not have seen the commercialization of…
Watch Now
White Papers
With more momentum than ever to bring innovative medicines to market, there is increased pressure on emerging companies to get the launch right. The industry has seen record-breaking funding for therapies in recent years, and many have been commercialized by emerging biopharma companies launching for the first time. For many of these emerging biopharma companies, optimizing commercial launch spend is a critical consideration pre- and post-launch, and with limited funds it can be easy to misjudge the timing of key…
Read Now
Podcasts
The importance of ensuring diversity in clinical trials is undisputed, but barriers across the healthcare ecosystem still exist; what can healthcare regulators, policy makers, and manufacturers do to overcome challenges when recruiting clinical trial participants?
Host, Matthew Rube, a Senior Consultant at Trinity Life Sciences, joins two of the subject-matter experts that authored Trinity Life Sciences’ cornerstone white paper to discuss why ensuring diversity in clinical trials participation is such a critical issue, the results of the team’s research, and…
Listen Now
Webinars
Available On Demand
Whether you are an emerging, mid-tier or large-tier company preparing for launch, now is the time to challenge conventional thinking.
We have all seen the dramatic shifts in scientific innovation in the life sciences industry that have been further accelerated by the COVID-19 pandemic. Despite these shifts, Trinity Life Sciences found that the commercial models employed by companies that launched new products recently were still largely based on traditional sales and marketing approaches.
In reaction to these findings, our experts…
Watch Now
Webinars
Available On Demand
What do ‘pricing inflation penalties’ actually mean for manufacturers of biopharma products?
Explore the impact of the Inflation Reduction Act (IRA) on biopharmaceutical product net prices and contract strategies as manufacturers adapt to new U.S. market conditions.
In this webinar, Trinity Life Sciences’ Evidence, Value, Access & Pricing practice experts will provide a high-level review of IRA policy updates before exploring the implications for currently marketed Medicare Part B and Part D therapies, as well as for future product launches.…
Watch Now
Webinars
Available On Demand
Demonstrating and communicating the value story to clinicians and payers is critical for successful commercialization, but there are many scenarios where new products may struggle to differentiate themselves. If you have a better mousetrap, how do you demonstrate value to support pricing, access, adoption and reimbursement?
The HEOR Evidence Strategy team at Trinity Life Sciences will conduct a webinar to explore this important question and share several case studies where we worked with companies facing this challenge. We will also…
Watch Now
